Zila's OraTest Rinse Needs Additional Study, FDA Advisory Committee Says
This article was originally published in The Gray Sheet
Zila should conduct another trial of its OraTest oral cancer diagnostic, FDA's Oncology Drugs Advisory Committee determined Jan. 13.
You may also be interested in...
Zila Medical's strategy of seeking an adjunctive claim for its ZTC tolonium chloride compound enabled a relatively quick device review, CEO Douglas Burkett said in a Feb. 7 conference call
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.